Alonso Heredia

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201
    Proc Natl Acad Sci U S A 112:9412-7. 2015
  2. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
  3. pmc Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    Antimicrob Agents Chemother 51:2489-96. 2007
  4. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
  5. doi request reprint Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Antiviral Res 83:86-9. 2009
  6. pmc An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence
    Brian M Taylor
    Institute of Human Virology, School of Medicine, and Department of Microbiology and Immunology, University of Maryland Baltimore, 725 W Lombard St, Baltimore, Maryland 21201, USA
    J Virol 82:5460-71. 2008
  7. ncbi request reprint Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    AIDS 19:2087-95. 2005
  8. pmc Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
    AIDS 25:1232-5. 2011
  9. pmc Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland
    J Infect Dis 208:2085-94. 2013
  10. ncbi request reprint Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120
    Jingsong Wang
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    Org Biomol Chem 3:1781-6. 2005

Collaborators

Detail Information

Publications23

  1. pmc Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201
    Proc Natl Acad Sci U S A 112:9412-7. 2015
    ..Targeting of cellular mTOR with INK128 (and perhaps others TOR-KIs) provides a potential strategy to inhibit HIV, especially in patients with drug resistant HIV strains. ..
  2. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
    ....
  3. pmc Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    Antimicrob Agents Chemother 51:2489-96. 2007
    ....
  4. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
    ..In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1...
  5. doi request reprint Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Antiviral Res 83:86-9. 2009
    ..Combinations of RAPA and CCR5 antagonists could provide an effective means to control drug-resistant R5 HIV in patients, most notably those infected with Maraviroc-resistant viruses...
  6. pmc An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence
    Brian M Taylor
    Institute of Human Virology, School of Medicine, and Department of Microbiology and Immunology, University of Maryland Baltimore, 725 W Lombard St, Baltimore, Maryland 21201, USA
    J Virol 82:5460-71. 2008
    ....
  7. ncbi request reprint Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    AIDS 19:2087-95. 2005
    ..To evaluate the effects of the cyclin dependent kinase (CDK) inhibitor Indirubin-3'-monoxime (IM) on Tat-mediated transactivation function, a step of the HIV-1 cycle that is not currently targeted in antiviral therapy...
  8. pmc Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
    AIDS 25:1232-5. 2011
    ..These data, together with the high barrier of resistance to HGS004, suggest that combinations of maraviroc and HGS004 could provide effective preventive and therapeutic strategies against R5 HIV-1...
  9. pmc Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland
    J Infect Dis 208:2085-94. 2013
    ..Resveratrol is a natural product that inhibits cellular ribonucleotide reductase, prolonging the S phase of the cell cycle and preferentially lowering dATP levels...
  10. ncbi request reprint Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120
    Jingsong Wang
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    Org Biomol Chem 3:1781-6. 2005
    ..But the polyacrylamide-based polyvalent compounds did not show inhibitory activity at up to 200 nM...
  11. ncbi request reprint Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein
    Hengguang Li
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore 21201, USA
    Bioconjug Chem 15:783-9. 2004
    ..The study suggests that targeting the oligomeric gp120 complex by novel multivalent ligands offers a valuable strategy for developing highly specific and effective HIV entry inhibitors...
  12. ncbi request reprint Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity
    Lai Xi Wang
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, 725 West Lombard Street, Baltimore, MD 21201, USA
    J Pharm Sci 93:2448-57. 2004
    ..The present studies have implications for future development of resveratrol and/or its derivatives as a chemotherapeutic agent...
  13. ncbi request reprint Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    AIDS 21:2108-10. 2007
    ..These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection...
  14. ncbi request reprint In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications
    Alonso Heredia
    Division of Clinical Research, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD, USA
    AIDS 19:836-7. 2005
    ..0015). These results suggest that vitamin E supplementation may interfere with the emergence of drug-resistant HIV-1 variants archived in the resting cell reservoir and delay or limit virus rebound upon treatment interruptions...
  15. pmc Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1
    Alonso Heredia
    aInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA bMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada cSan Francisco VA Medical Center and University of California, San Francisco, California, USA
    AIDS 28:317-23. 2014
    ..We hypothesized that lowering intracellular dNTPs with resveratrol, a dietary supplement, could interfere with replication of M184V HIV-1 mutants...
  16. pmc Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues
    Wei Huang
    Institute of Human Virology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA
    Chembiochem 10:1234-42. 2009
    ..These favorable properties suggest that the triazole-linked C34 glycopeptide might be valuable for further development as an anti-HIV drug candidate...
  17. pmc CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Virology 411:32-40. 2011
    ..Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance...
  18. ncbi request reprint HIV-1 natural viral suppressors: control of viral replication in the absence of therapy
    Mohammad M Sajadi
    Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA
    AIDS 21:517-9. 2007
    ..This ability to control HIV-1 viral replication naturally has led us to refer to them as natural viral suppressors...
  19. pmc Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, Biotechnology Institute, University of Maryland, 725 West Lombard Street, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 100:4179-84. 2003
    ....
  20. ncbi request reprint Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment
    Olga S Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard St, Baltimore, MD 21201, USA
    Curr HIV Res 14:24-36. 2016
    ..FLSC) IgG1, a fusion of FLSC and the hinge-C(H)2-C(H)3 region of human IgG1, has an increased antiviral activity, likely due to the resultant bivalency...
  21. doi request reprint Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
    Olga Latinovic
    Institute of Human Virology, University of Maryland, University of Maryland School of Medicine, Baltimore, MD, USA Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA
    Antiviral Res 112:80-90. 2014
    ..These data have implications for future antiviral therapy development...
  22. ncbi request reprint Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting
    Kannan P Naicker
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, MD 21201, USA
    Org Biomol Chem 2:660-4. 2004
    ....
  23. doi request reprint Impact of HIV on lung tumorigenesis in an animal model
    Shigeru Kawabata
    aDepartment of Oncology, Johns Hopkins University School of Medicine bInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    AIDS 29:633-5. 2015
    ..Adjuvant therapies that restore immunity and lower inflammation may decrease lung cancer mortality in HIV patients. ..